BSECompany Update25 Aug 2026 · 25 Aug 2026, 04:51 pm
Intimation of Schedule of the Investors/Analysts Meet
Akums Drugs and Pharmaceuticals Ltd · 544222
✦ AI Summary
Akums Drugs and Pharmaceuticals Ltd has informed about its participation in an investor/analysts meet on 2nd September 2026 at Hyatt, Santacruz, Mumbai. The meet is part of the India Dialogue 2026 and will start at 02:00 PM (IST). No unpublished price sensitive information will be shared during the meet.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Attachments (1)
📄pdf
Download →
9b0f1271-56ec-412a-a7df-7189d27553c1.pdf
View document text
Ref: Akums/Exchange/2026-27/47 August 25, 2026
To, To,
The Listing Department The Listing Department
National Stock Exchange of India Ltd BSE Limited
Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring,
Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy
Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001
Symbol: AKUMS Scrip Code: 544222
Sub: Intimation of Schedule of the Investors/Analysts Meet
Respected Sir/Ma’am,
This is to inform you that pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals
Limited (“the Company”) will participate in the below scheduled investor/analysts meet:
S. No. Particulars of Meet Date & Time of Type of Meet Location / Mode
Meeting of Meeting
1 Ashwamedh – Elara 2nd September, Group Meet Hyatt, Santacruz
India Dialogue 2026 2026; starts at East, Mumbai/
02:00 PM (IST) Physical
Further, no unpublished price sensitive information pertaining to the Company will be shared during
the meet with Analysts/Investors.
Please note that the above may subject to change due to exigencies on the part of Investors/analysts
or the Company.
A copy of this disclosure is being updated on website of the Company at www.akums.in
This is for your information and records.
For Akums Drugs and Pharmaceuticals Limited
Dharamvir Malik
Company Secretary & Compliance Officer